{"id":4317,"date":"2026-02-08T04:07:11","date_gmt":"2026-02-08T04:07:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/4317\/"},"modified":"2026-02-08T04:07:11","modified_gmt":"2026-02-08T04:07:11","slug":"hims-hers-launches-compounded-version-of-wegovy-novo-nordisk-threatens-legal-action-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/4317\/","title":{"rendered":"Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action"},"content":{"rendered":"\n

On Thursday, Hims & Hers Health Inc. (NYSE:<\/a>HIMS<\/a>) announced Thursday an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk A\/S’ (NYSE:<\/a>NVO<\/a>) Wegovy.<\/p>\n

Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.<\/p>\n

The new Compounded Semaglutide Pill is formulated to protect the active ingredient during digestion and to support absorption.<\/p>\n

Don’t Miss:<\/p>\n

In 2025, Hims & Hers doubled its facility footprint<\/a> to over one million square feet, integrating advanced pharmacy capabilities, lab testing, and R&D space.<\/p>\n

Hims & Hers said it adheres to all applicable federal and state regulatory standards for compounding.<\/p>\n

Soon after, Novo Nordisk issued a statement regarding the announcement by Hims & Hers.<\/p>\n

Novo Nordisk stock is already under pressure on a softer outlook for fiscal 2026<\/a>.<\/p>\n

The Dutch pharma giant said Hims & Hers will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill.<\/p>\n

“The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action\u2026” This is another example of Hims & Hers’ historic behaviour of duping the American public with knockoff GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knockoffs.”<\/p>\n

See Also: Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.<\/a><\/p>\n

Only Novo Nordisk manufactures an FDA-approved\u00a0Wegovy pill formulated with SNAC technology, which facilitates\u00a0semaglutide absorption when administered orally.<\/p>\n

The Wegovy pill is available in all doses, in full supply. Compounded semaglutide is not approved by the FDA and may contain impurities, unnecessary additives,\u00a0and untested doses, Novo Nordisk said on Thursday.<\/p>\n

In June 2025, Hims & Hers’ stock cratered almost 30% when Novo Nordisk discontinued working with the company in relation to direct access to Wegovy (semaglutide)<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by…\n","protected":false},"author":2,"featured_media":4318,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1167,621,272],"class_list":{"0":"post-4317","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-compounded-semaglutide","9":"tag-hims","10":"tag-novo-nordisk"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/4317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=4317"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/4317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/4318"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=4317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=4317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=4317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}